Carlo Croce

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. pmc mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer
    Giovanni Lanza
    Department of Experimental and Diagnostic Medicine and Interdepartment Center for Cancer Research, University of Ferrara, Ferrara, Italy
    Mol Cancer 6:54. 2007
  2. pmc MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
    Marilena V Iorio
    Start Up Unit, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milano, Italy
    EMBO Mol Med 4:143-59. 2012
  3. pmc UCbase & miRfunc: a database of ultraconserved sequences and microRNA function
    Cristian Taccioli
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Nucleic Acids Res 37:D41-8. 2009
  4. pmc Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel
    Eugenio Gaudio
    Department of Molecular Immunology, Virology and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland Dipartimento di Medicina Sperimentale e Clinica, University Magna Græcia, Campus S Venuta, Catanzaro, Italy
    PLoS ONE 8:e78610. 2013
  5. pmc p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
    Taewan Kim
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, 2 Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA
    J Exp Med 208:875-83. 2011
  6. pmc EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Nat Med 18:74-82. 2012
  7. pmc MicroRNA in cancer: new hopes for antineoplastic chemotherapy
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology and Human Genetics, Ohio State University, Columbus, OH 43210, USA
    Ups J Med Sci 117:202-16. 2012
  8. pmc MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia
    Rosa Visone
    Department of Oncology and Experimental Medicine, G D Annunzio University, 66100, Chieti, Italy
    Oncotarget 3:195-202. 2012
  9. pmc MicroRNAs: new players in acute myeloid leukaemia
    V Havelange
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Cancer 101:743-8. 2009
  10. pmc Genome wide identification of recessive cancer genes by combinatorial mutation analysis
    Stefano Volinia
    Data Mining for Analysis of Microarrays, Universita degli Studi, Ferrara, Italy
    PLoS ONE 3:e3380. 2008

Detail Information

Publications119 found, 100 shown here

  1. pmc mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer
    Giovanni Lanza
    Department of Experimental and Diagnostic Medicine and Interdepartment Center for Cancer Research, University of Ferrara, Ferrara, Italy
    Mol Cancer 6:54. 2007
    ..Colorectal cancer develops through two main genetic instability pathways characterized by distinct pathologic features and clinical outcome...
  2. pmc MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
    Marilena V Iorio
    Start Up Unit, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milano, Italy
    EMBO Mol Med 4:143-59. 2012
    ..Here, we review our current knowledge about the involvement of microRNAs in cancer, and their potential as diagnostic, prognostic and therapeutic tools...
  3. pmc UCbase & miRfunc: a database of ultraconserved sequences and microRNA function
    Cristian Taccioli
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, OH 43210, USA
    Nucleic Acids Res 37:D41-8. 2009
    ..The current release contains over 2000 sequences from three species (human, mouse and rat). As a web application, UCbase & miRfunc is platform independent and it is accessible at http://microrna.osu.edu/.UCbase4...
  4. pmc Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel
    Eugenio Gaudio
    Department of Molecular Immunology, Virology and Medical Genetics, The Ohio State University, Columbus, Ohio, United States of America Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland Dipartimento di Medicina Sperimentale e Clinica, University Magna Græcia, Campus S Venuta, Catanzaro, Italy
    PLoS ONE 8:e78610. 2013
    ..Moreover, paclitaxel administration in combination with AdFHIT acts synergistically to increase the apoptotic rate of tumor cells both in vitro and in vivo experiments. ..
  5. pmc p53 regulates epithelial-mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
    Taewan Kim
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, 2 Molecular, Cellular, and Developmental Biology Program, The Ohio State University, Columbus, OH 43210, USA
    J Exp Med 208:875-83. 2011
    ..Inhibition or overexpression of the miRNAs affects p53-regulated EMT by altering ZEB1 and ZEB2 expression. Our findings indicate that p53 can regulate EMT, and that p53-regulated miRNAs are critical mediators of p53-regulated EMT...
  6. pmc EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Nat Med 18:74-82. 2012
    ..These findings suggest that modulation of specific miRNAs may provide a therapeutic approach for the treatment of NSCLCs...
  7. pmc MicroRNA in cancer: new hopes for antineoplastic chemotherapy
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology and Human Genetics, Ohio State University, Columbus, OH 43210, USA
    Ups J Med Sci 117:202-16. 2012
    ..We will also highlight the literature where application of miRNAs has created the foundation for the development of potential future miRNA therapy...
  8. pmc MiR-181b: new perspective to evaluate disease progression in chronic lymphocytic leukemia
    Rosa Visone
    Department of Oncology and Experimental Medicine, G D Annunzio University, 66100, Chieti, Italy
    Oncotarget 3:195-202. 2012
    ..Here, we discuss more extensively this issue by adding novel findings and introducing a novel approach for monitoring CLL patients...
  9. pmc MicroRNAs: new players in acute myeloid leukaemia
    V Havelange
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Br J Cancer 101:743-8. 2009
    ..Aberrant miRNA expression has been described in acute myeloid leukaemia suggesting a role in leukaemogenesis. In this review we summarise the current knowledge...
  10. pmc Genome wide identification of recessive cancer genes by combinatorial mutation analysis
    Stefano Volinia
    Data Mining for Analysis of Microarrays, Universita degli Studi, Ferrara, Italy
    PLoS ONE 3:e3380. 2008
    ..5% genes. The functions significantly affected by cancer mutations are exactly overlapping those of known cancer genes, with the critical exception for the absence of tyrosine kinases, as expected for a recessive gene-set...
  11. pmc The Role of microRNAs in the Tumorigenesis of Ovarian Cancer
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University Columbus, OH, USA
    Front Oncol 3:153. 2013
    ....
  12. pmc Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology, and Medical Genetics, School of Medicine, The Ohio State University, Columbus, Ohio, United States of America
    PLoS Genet 9:e1003311. 2013
    ..Importantly, we demonstrated that the miR-191/425 cluster, by reducing the expression of an extensive network of genes, has a fundamental impact on cancer initiation and progression of breast cancer cells...
  13. pmc Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer
    Robert S Hudson
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Mol Cancer 12:13. 2013
    ..We hypothesized that ucRNAs have unidentified roles in the pathogenesis of human prostate cancer. In a pilot study, we examined ucRNA expression profiles in human prostate tumors...
  14. pmc MicroRNA miR-30 family regulates non-attachment growth of breast cancer cells
    Maria Ouzounova
    Epigenetics Group, International Agency for Research on Cancer IARC, 150 rue Albert Thomas, Lyon, 69008, France
    BMC Genomics 14:139. 2013
    ..To explore the notion that miRNAs may have a role in sustaining BT-ICs, we performed a comprehensive profiling of miRNA expression in a model of putative BT-ICs enriched by non-attachment growth conditions...
  15. pmc Mammalian microRNAs: a small world for fine-tuning gene expression
    Cinzia Sevignani
    Department of Microbiology and Immunology, Kimmel Cancer Center, Jefferson Medical College, Philadelphia, PA 19107, USA
    Mamm Genome 17:189-202. 2006
    ..We argue that developing mouse models for deleted and/or overexpressed microRNAs will be of invaluable interest to decipher the regulatory networks where microRNAs are involved...
  16. pmc MicroRNA expression profiling of male breast cancer
    Matteo Fassan
    Department of Urology, Thomas Jefferson University Kimmel Cancer Center, 1112 College Building, 1025 Walnut Street, PA 19107, USA
    Breast Cancer Res 11:R58. 2009
    ....
  17. pmc Compatible solutes from hyperthermophiles improve the quality of DNA microarrays
    Nicoletta Mascellani
    Dipartimento di Morfologia ed Embriologia and DAMA, Data Mining for Analysis of DNA Microarrays, Telethon Facility, Universita degli Studi di Ferrara, Ferrara, Italy
    BMC Biotechnol 7:82. 2007
    ..Compatible solutes show stabilization effects towards biological macromolecules, including DNA...
  18. doi request reprint Oncogenes and cancer
    Carlo M Croce
    Department of Molecular Virology, Immunology, and Medical Genetics and the Human Cancer Genetics Program, Ohio State University Medical Center, Columbus, OH 43210, USA
    N Engl J Med 358:502-11. 2008
  19. pmc Causes and consequences of microRNA dysregulation in cancer
    Carlo M Croce
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University Medical Center, 410 West 10th Avenue, Columbus, OH 43210, USA
    Nat Rev Genet 10:704-14. 2009
    ....
  20. pmc Fez1/Lzts1 a new mitotic regulator implicated in cancer development
    Andrea Vecchione
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, OH, USA
    Cell Div 2:24. 2007
    ..Recently we identified a new player: FEZ1/LZTS1 that contributes to the fine-tuning of the molecular events that determine progression through mitosis, and here will review its role in cancer development and in M phase regulation...
  21. ncbi request reprint MicroRNA dysregulation in cancer: opportunities for the development of microRNA-based drugs
    S Patrick Nana-Sinkam
    Ohio State University, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, 473 West 12th Avenue, Columbus, Ohio 43210, USA
    IDrugs 13:843-6. 2010
    ..This feature review discusses the current status of therapeutic approaches for miRNA in cancer, as well as potential challenges and future strategies...
  22. doi request reprint E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer
    Fabio Petrocca
    Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Ohio State University, 460 West 12th Avenue, Columbus, OH 43210, USA
    Cancer Cell 13:272-86. 2008
    ..Together, these results suggest that the miR-106b-25 cluster is involved in E2F1 posttranscriptional regulation and may play a key role in the development of TGFbeta resistance in gastric cancer...
  23. pmc Methylation mediated silencing of MicroRNA-1 gene and its role in hepatocellular carcinogenesis
    Jharna Datta
    Department of Molecular and Cellular Biochemistry, College of Pharmacy, and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 68:5049-58. 2008
    ..The inhibition of cell cycle progression and induction of apoptosis after re-expression of miR-1 are some of the mechanisms by which DNA hypomethylating agents suppress hepatocarcinoma cell growth...
  24. pmc The role of microRNA genes in papillary thyroid carcinoma
    Huiling He
    Human Cancer Genetics Program, Department of Pathology, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 102:19075-80. 2005
    ..We conclude that up-regulation of several miRs and regulation of KIT are involved in PTC pathogenesis, and that sequence changes in genes targeted by miRNAs can contribute to their regulation...
  25. pmc MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1
    Ramiro Garzon
    Department of Medicine, Ohio State University, Columbus, 43210, USA
    Blood 113:6411-8. 2009
    ....
  26. ncbi request reprint Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD
    Esmerina Tili
    Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Biomedical Tower, 460 West 12th Avenue, Columbus, OH 43210, USA
    Carcinogenesis 31:1561-6. 2010
    ....
  27. ncbi request reprint Preclinical assessment of FHIT gene replacement therapy in human leukemia using a chimeric adenovirus, Ad5/F35
    Flavia Pichiorri
    Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 12:3494-501. 2006
    ..We have generated a chimeric FHIT-containing adenovirus composed of Ad5 and the group B adenovirus called F35 with which we have been able to efficiently infect hematopoietic cells...
  28. pmc MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer
    Gianpiero Di Leva
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, 460 West, 12th Ave, Columbus, OH 43210, USA
    J Natl Cancer Inst 102:706-21. 2010
    ..Because microRNAs (miRNAs) modulate gene expression, we hypothesized that they may have a role in ER-negative tumor formation...
  29. pmc Knockout mice reveal a tumor suppressor function for Testin
    Alessandra Drusco
    Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 102:10947-51. 2005
    ..A statistically significant difference in tumor incidence was found between +/- versus +/+ and -/- versus +/+ (P < 0.0001). These data suggest that Tes functions as a tumor suppressor gene in vivo...
  30. pmc Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin
    Ramiro Garzon
    Departments of Medicine and Molecular Virology and Human Genetics, Comprehensive Cancer Center, and College of Pharmacology, Ohio State University, Columbus, OH 43221, USA
    Proc Natl Acad Sci U S A 105:3945-50. 2008
    ..Moreover, we found that miR-155 was strongly but independently associated with FLT3-ITD mutations...
  31. pmc MicroRNA 29b functions in acute myeloid leukemia
    Ramiro Garzon
    Division of Hematology and Oncology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA
    Blood 114:5331-41. 2009
    ..Together, the data support a tumor suppressor role for miR-29 and provide a rationale for the use of synthetic miR-29b oligonucleotides as a novel strategy to improve treatment response in AML...
  32. ncbi request reprint Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency
    Nicola Zanesi
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:6576-82. 2005
    ....
  33. pmc Epigenetic changes during disease progression in a murine model of human chronic lymphocytic leukemia
    Shih Shih Chen
    Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 106:13433-8. 2009
    ..These results provide strong rationale for the development of strategies to target NF-kappaB components in CLL and potentially other B-cell malignancies...
  34. pmc NF-kappaB-YY1-miR-29 regulatory circuitry in skeletal myogenesis and rhabdomyosarcoma
    Huating Wang
    Department of Molecular Virology, Human Cancer Genetics Program, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 14:369-81. 2008
    ..Together, these results identify a NF-kappaB-YY1-miR-29 regulatory circuit whose disruption may contribute to RMS...
  35. pmc MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis
    Flavia Pichiorri
    Department of Molecular Virology, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:12885-90. 2008
    ..In summary, we have described a MM miRNA signature, which includes miRNAs that modulate the expression of proteins critical to myeloma pathogenesis...
  36. doi request reprint MicroRNAs in cancer: personalizing diagnosis and therapy
    S Patrick Nana-Sinkam
    Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, The Ohio State University, Columbus, Ohio 43210, USA
    Ann N Y Acad Sci 1210:25-33. 2010
    ....
  37. pmc Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice
    Bo Wang
    Department of Molecular and Cellular Biochemistry, Ohio State University, Columbus, OH, USA
    Hepatology 50:1152-61. 2009
    ..Notably, miR-155 was significantly (P = 0.0004) up-regulated in primary human HCCs with a concomitant decrease (P = 0.02) in C/EBPbeta level compared with matching liver tissues...
  38. pmc Correlation of fragile histidine triad (Fhit) protein structural features with effector interactions and biological functions
    Flavia Pichiorri
    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University and Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    J Biol Chem 284:1040-9. 2009
    ....
  39. pmc Modulation of mismatch repair and genomic stability by miR-155
    Nicola Valeri
    Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University Medical Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:6982-7. 2010
    ..Finally, a number of MSI tumors with unknown cause of MMR inactivation displayed miR-155 overexpression. These data provide support for miR-155 modulation of MMR as a mechanism of cancer pathogenesis...
  40. ncbi request reprint Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis
    Tetsuya Ueda
    Department of Molecular Virology, Immunology, Ohio State University, Columbus, OH 43210, USA
    Lancet Oncol 11:136-46. 2010
    ..We aimed to assess the relation between microRNA expression and progression and prognosis of gastric cancer...
  41. ncbi request reprint Physical association with WWOX suppresses c-Jun transcriptional activity
    Eugenio Gaudio
    Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 66:11585-9. 2006
    ..Our findings reveal a novel functional cross-talk between c-Jun transcription factor and WWOX tumor suppressor protein...
  42. ncbi request reprint A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention
    Nicola Zanesi
    Comprehensive Cancer Center, Ohio State University, 400 W 12th Avenue, Columbus, OH, USA
    Mutat Res 591:103-9. 2005
    ..Insights into Fhit mouse genetics that have emerged in the last 7 years, and are reviewed in the present article, allowed for development of new tools in carcinogenesis and gene delivery studies...
  43. pmc MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B
    Muller Fabbri
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, and College of Pharmacy, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 104:15805-10. 2007
    ..These findings support a role of miR-29s in epigenetic normalization of NSCLC, providing a rationale for the development of miRNA-based strategies for the treatment of lung cancer...
  44. doi request reprint MicroRNAs modulate the chemosensitivity of tumor cells
    Paul E Blower
    Program of Pharmacogenomics, Department of Pharmacology, Ohio State University, 333 West Tenth Street, Columbus, OH 43210, USA
    Mol Cancer Ther 7:1-9. 2008
    ..Ten of those microRNAs have already been implicated in cancer biology. Our results support a substantial role for microRNAs in anticancer drug response, suggesting novel potential approaches to the improvement of chemotherapy...
  45. doi request reprint The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform
    Kimberly E Resnick
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, Ohio 43210, USA
    Gynecol Oncol 112:55-9. 2009
    ..To determine the utility of serum miRNAs as biomarkers for epithelial ovarian cancer...
  46. pmc 13q14 deletions in CLL involve cooperating tumor suppressors
    Alexey Palamarchuk
    Human Cancer Genetics Program and Comprehensive Cancer Center, Department of Molecular Virology, Immunology and Medical Genetics, School of Medicine, Ohio State University, Columbus, OH, USA
    Blood 115:3916-22. 2010
    ..In addition, DLEU7 expression in A549 lung cancer cells resulted in a decrease in S phase and increased apoptosis. The results suggest that loss of DLEU7 may cooperate with the loss of miR-15/16 in the pathogenesis of CLL...
  47. ncbi request reprint MicroRNAs
    Muller Fabbri
    Human Cancer Genetics, Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, OH, USA
    Cancer J 14:1-6. 2008
    ..miRNA expression levels have diagnostic and prognostic implications, and their roles as anticancer therapeutic agents is promising and currently under investigation...
  48. ncbi request reprint Biological functions of mammalian Nit1, the counterpart of the invertebrate NitFhit Rosetta stone protein, a possible tumor suppressor
    Shuho Semba
    Comprehensive Cancer Center and Department of Molecular Virology, Immunology, and Medical Genetics, The Ohio State University, Columbus, 43210, USA
    J Biol Chem 281:28244-53. 2006
    ....
  49. pmc MiR-15a and miR-16-1 cluster functions in human leukemia
    George A Calin
    Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:5166-71. 2008
    ..By examining the Gene Ontology (GO) database, a significant enrichment in cancer genes (such as MCL1, BCL2, ETS1, or JUN) that directly or indirectly affect apoptosis and cell cycle was found...
  50. doi request reprint Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling
    Fabio Petrocca
    Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 68:8191-4. 2008
    ....
  51. pmc WWOX gene restoration prevents lung cancer growth in vitro and in vivo
    Muller Fabbri
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, Ohio State University, 410 West 12th Avenue, Columbus, OH 43201, USA
    Proc Natl Acad Sci U S A 102:15611-6. 2005
    ..This study confirms that WWOX is a tumor suppressor gene and is highly effective in preventing growth of lung cancer xenografts, whether introduced through viral infection or by induction of a silent WWOX transgene...
  52. ncbi request reprint A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia
    George Adrian Calin
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    N Engl J Med 353:1793-801. 2005
    ..We investigated whether microRNA profiles are associated with known prognostic factors in CLL...
  53. ncbi request reprint MicroRNA expression and function in cancer
    Ramiro Garzon
    Department of Virology, Immunology and Human Genetics, and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Trends Mol Med 12:580-7. 2006
    ..Here, we summarize miRNA-profiling studies in human malignancies and examine the role of miRNAs in the pathogenesis of cancer. We also discuss the implications of these findings for the diagnosis and treatment of cancer...
  54. ncbi request reprint MicroRNA signatures in human cancers
    George A Calin
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Nat Rev Cancer 6:857-66. 2006
    ..In addition, profiling has been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or that target protein-coding genes involved in cancer...
  55. pmc Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development
    Andrea Vecchione
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 11:275-89. 2007
    ..Accordingly, Lzts1 deficiency was associated with an increased incidence of both spontaneous and carcinogen-induced cancers in mice...
  56. ncbi request reprint Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas
    George A Calin
    Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 12:215-29. 2007
    ..Our findings argue that ncRNAs and interaction between noncoding genes are involved in tumorigenesis to a greater extent than previously thought...
  57. pmc Zinc replenishment reverses overexpression of the proinflammatory mediator S100A8 and esophageal preneoplasia in the rat
    Cristian Taccioli
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA
    Gastroenterology 136:953-66. 2009
    ..Zinc-replenishment reverses proliferation and inhibits carcinogenesis. The zinc-deficient rat model allows the identification of biological differences affected by zinc during early esophageal carcinogenesis...
  58. pmc Hepatic miR-29ab1 expression modulates chronic hepatic injury
    Takayuki Kogure
    College of Medicine, Ohio State University, Columbus, OH, USA
    J Cell Mol Med 16:2647-54. 2012
    ..These results provide evidence of the involvement of miR-29 in chronic hepatic injury, and suggest a role for deregulated hepatocyte expression of miR-29 in the response to hepatic injury, fibrosis and carcinogenesis...
  59. doi request reprint MicroRNAs, the immune system and rheumatic disease
    Esmerina Tili
    Molecular Virology, Immunology and Medical Genetics Department, The Ohio State University, Columbus, OH 43210, USA
    Nat Clin Pract Rheumatol 4:534-41. 2008
    ..Abnormal expression of miRNAs-which is implicated in inflammation-has also been found in patients with rheumatoid arthritis. These findings identify miRNAs as critical targets for immunomodulatory drug development...
  60. pmc Tcl1 functions as a transcriptional regulator and is directly involved in the pathogenesis of CLL
    Yuri Pekarsky
    Human Cancer Genetics Program, Comprehensive Cancer Center, Department of Molecular Virology, Immunology, and Medical Genetics, School of Medicine, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 105:19643-8. 2008
    ..Importantly, both mutants showed gain of function as AP-1 inhibitors. The results indicate that Tcl1 overexpression causes B-CLL by directly enhancing NF-kappaB activity and inhibiting AP-1...
  61. pmc Fhit tumor suppressor: guardian of the preneoplastic genome
    Flavia Pichiorri
    Ohio State University Comprehensive Cancer Center, Department of Molecular Virology, Molecular Virology and Medical Genetics 460 W 12th Avenue, 43210 Columbus, OH, USA
    Future Oncol 4:815-24. 2008
    ....
  62. pmc Karyotype-specific microRNA signature in chronic lymphocytic leukemia
    Rosa Visone
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Blood 114:3872-9. 2009
    ..Thus, the use of the microRNA-based classifications may yield clinically useful biomarkers of tumor behavior in CLL...
  63. ncbi request reprint Akt phosphorylates Tal1 oncoprotein and inhibits its repressor activity
    Alexey Palamarchuk
    Human Cancer Genetics Program, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:4515-9. 2005
    ..2) promoter. Thus, these data indicate that Akt interacts with Tal1 and regulates Tal1 by phosphorylation at Thr90 in a phosphatidylinositol 3-kinase-dependent manner...
  64. ncbi request reprint MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias
    Guido Marcucci
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, 320 West 10th Avenue, Columbus, OH, USA
    Best Pract Res Clin Haematol 22:239-48. 2009
    ..We review herein results of current studies analysing changes of microRNA expression in acute myeloid leukaemia and chronic lymphocytic leukaemia, and discuss their potential biologic, diagnostic and prognostic relevance...
  65. pmc Sp1/NFkappaB/HDAC/miR-29b regulatory network in KIT-driven myeloid leukemia
    Shujun Liu
    Division of Hematology Oncology, The Ohio State University, Columbus, OH 43210, USA
    Cancer Cell 17:333-47. 2010
    ....
  66. pmc Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression
    Urmila Santanam
    Department of Molecular Virology, Ohio State University School of Medicine, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 107:12210-5. 2010
    ..Of 20 Emu-miR-29 transgenic mice followed to 24-26 mo of age, 4 (20%) developed frank leukemia and died of the disease. These results suggest that dysregulation of miR-29 can contribute to the pathogenesis of indolent B-CLL...
  67. ncbi request reprint MicroRNAs in the ontogeny of leukemias and lymphomas
    Muller Fabbri
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    Leuk Lymphoma 50:160-70. 2009
    ....
  68. doi request reprint microRNAs: Master regulators as potential therapeutics in cancer
    Michela Garofalo
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, 43210, USA
    Annu Rev Pharmacol Toxicol 51:25-43. 2011
    ....
  69. pmc Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis
    Rami I Aqeilan
    Department of Molecular Virology, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Endocrinology 150:1530-5. 2009
    ..These results demonstrate the essential requirement for the Wwox tumor suppressor in proper steroidogenesis...
  70. pmc A microRNA expression signature of human solid tumors defines cancer gene targets
    Stefano Volinia
    Department of Molecular Virology, Immunology, and Medical Genetics and Cancer Comprehensive Center, Ohio State University, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 103:2257-61. 2006
    ..Our results indicate that miRNAs are extensively involved in cancer pathogenesis of solid tumors and support their function as either dominant or recessive cancer genes...
  71. ncbi request reprint MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior
    Claudia Roldo
    Department of Molecular Virology, Immunology and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA
    J Clin Oncol 24:4677-84. 2006
    ..Recent evidence indicates that microRNAs can contribute to tumor development and progression and may have diagnostic and prognostic value in several human malignancies...
  72. ncbi request reprint Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer
    Fabio Petrocca
    Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 66:10287-91. 2006
    ....
  73. ncbi request reprint WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function
    Rami I Aqeilan
    Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43220, USA
    Cancer Res 65:6764-72. 2005
    ..In summary, our data indicate that WWOX antagonizes the function of YAP by competing for interaction with ErbB-4 and other targets and thus affect its transcriptional activity...
  74. ncbi request reprint miRNAs, cancer, and stem cell division
    Carlo M Croce
    Department of Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Cell 122:6-7. 2005
    ..As a cluster of recent Nature papers now show, altered expression of specific miRNA genes contributes to the initiation and progression of cancer...
  75. ncbi request reprint Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181
    Yuri Pekarsky
    Comprehensive Cancer Center, Human Cancer Genetics Program and Department of Molecular Virology, Immunology, and Medical Genetics, OSU School of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 66:11590-3. 2006
    ..Our results suggest that Tcl1 expression in CLL is, at least in part, regulated by miR-29 and miR-181 and that these microRNAs may be candidates for therapeutic agents in CLLs overexpressing Tcl1...
  76. pmc Targeted deletion of Wwox reveals a tumor suppressor function
    Rami I Aqeilan
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, Ohio State University, 410 West 12th Avenue, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 104:3949-54. 2007
    ..Intriguingly, these tumors still express Wwox protein, suggesting haploinsuffiency of WWOX itself is cancer predisposing. These results indicate that WWOX is a bona fide tumor suppressor...
  77. ncbi request reprint A role for the WWOX gene in prostate cancer
    Haiyan R Qin
    Department of Molecular Virology, Immunology, and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Cancer Res 66:6477-81. 2006
    ..The data are consistent with a role for WWOX as a prostate cancer tumor suppressor and suggest that WWOX signal pathways should be further investigated in normal and cancerous prostate cells and tissues...
  78. pmc Inactivation of the Wwox gene accelerates forestomach tumor progression in vivo
    Rami I Aqeilan
    Division of Human Cancer Genetics, Department of Molecular Virology, Immunology and Medical Genetics, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 67:5606-10. 2007
    ....
  79. ncbi request reprint MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis
    Mark Bloomston
    Division of Surgical Oncology, James Cancer Hospital and Solove Research Institute, Ohio State University, Columbus, USA
    JAMA 297:1901-8. 2007
    ..While global microRNA (miRNA) expression patterns of many embryologic, physiologic, and oncogenic processes have been described, description of the role of miRNAs in ductal adenocarcinoma of the pancreas is lacking...
  80. pmc Fhit interaction with ferredoxin reductase triggers generation of reactive oxygen species and apoptosis of cancer cells
    Francesco Trapasso
    Ohio State University, Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    J Biol Chem 283:13736-44. 2008
    ..Characterization of Fhit interacting proteins has identified direct effectors of the Fhit-mediated apoptotic pathway that is lost in most cancers through loss of Fhit...
  81. ncbi request reprint Animal models for chronic lymphocytic leukemia
    Yuri Pekarsky
    Comprehensive Cancer Center, Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, OSU School of Medicine, Ohio State University, Columbus, Ohio 43210, USA
    J Cell Biochem 100:1109-18. 2007
    ..In this article, we present what has been learned from mice with B-CLL phenotype and how these mouse models of B-CLL were used to test therapeutic treatments for this common leukemia...
  82. pmc The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism
    Rami I Aqeilan
    Department of Molecular Virology, Immunology, and Medical Genetics, Human Cancer Genetics Program and Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210, USA
    J Biol Chem 283:21629-39. 2008
    ..Our results demonstrate an essential requirement for the WWOX tumor suppressor in postnatal survival, growth, and metabolism and suggest a central role for WWOX in regulation of bone tissue formation...
  83. doi request reprint Primary intrathyroidal paraganglioma: histopathology and novel molecular alterations
    Stefan Costinean
    Department of Pathology, The Ohio State University, College of Medicine, Columbus, OH 43210, USA
    Hum Pathol 43:2371-5. 2012
    ..The presence of these genetic abnormalities may have therapeutic implications...
  84. ncbi request reprint MicroRNAs in leukemia
    Carlo Croce
    College of Medicine and Public Health, Molecular Virology, Immunology and Medical Genetics Human Cancer Genetics, Ohio State University Medical Center, Columbus, OH 43210, USA
    Clin Adv Hematol Oncol 4:577-8. 2006
  85. pmc MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival
    Mary Dillhoff
    Department of Surgery, The Ohio State University, 410 W 10th Ave, N924 Doan Hall, Columbus, OH 43210, USA
    J Gastrointest Surg 12:2171-6. 2008
    ..We sought to determine the expression pattern of miR-21 in pancreatic cancers and its impact on clinicopathologic characteristics...
  86. ncbi request reprint MicroRNA gene expression deregulation in human breast cancer
    Marilena V Iorio
    Comprehensive Cancer Center, Ohio State University, Columbus, Ohio 43210, USA
    Cancer Res 65:7065-70. 2005
    ..We could identify miRNAs whose expression was correlated with specific breast cancer biopathologic features, such as estrogen and progesterone receptor expression, tumor stage, vascular invasion, or proliferation index...
  87. ncbi request reprint ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation
    Tatsuya Nakamura
    Kimmel Cancer Center and Department of Microbiology, Jefferson Medical College, Philadelphia, PA 19107, USA
    Mol Cell 10:1119-28. 2002
    ..In parallel, H3-K4 is methylated, and histones H3 and H4 are acetylated at this promoter...
  88. pmc Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
    George Adrian Calin
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 99:15524-9. 2002
    ..Detailed deletion and expression analysis shows that miR15 and miR16 are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority ( approximately 68%) of CLL cases...
  89. ncbi request reprint Familial cancer associated with a polymorphism in ARLTS1
    George Adrian Calin
    Thomas Jefferson University, Philadelphia, USA
    N Engl J Med 352:1667-76. 2005
    ..The finding of hemizygous or homozygous deletions at band 14 on chromosome 13 in a variety of neoplasms suggests the presence of a tumor-suppressor locus telomeric to the RB1 gene...
  90. ncbi request reprint p53 deficiency accelerates induction and progression of esophageal and forestomach tumors in zinc-deficient mice
    Louise Y Y Fong
    Kimmel Cancer Center, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Res 63:186-95. 2003
    ..Our findings provide in vivo evidence for the collaboration of a deficiency of both p53 and zinc in esophageal carcinogenesis and reveal molecular targets of this collaboration...
  91. ncbi request reprint Promoter hypermethylation of RASSF1A in esophageal squamous cell carcinoma
    Tamotsu Kuroki
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania, Pennsylvania 19107, USA
    Clin Cancer Res 9:1441-5. 2003
    ..The aim of this study was to evaluate the promoter methylation status of the RASSF1A in esophageal squamous cell carcinoma...
  92. ncbi request reprint WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer
    Sai Yendamuri
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Res 63:878-81. 2003
    ..0%). We conclude that WWOX alterations occur in a significant fraction of lung cancers and may contribute to the pathogenesis of non-small cell lung cancer...
  93. ncbi request reprint Restoration of receptor-type protein tyrosine phosphatase eta function inhibits human pancreatic carcinoma cell growth in vitro and in vivo
    Francesco Trapasso
    Kimmel Cancer Institute, Thomas Jefferson University, 233S 10th Street, Philadelphia, PA 19107, USA
    Carcinogenesis 25:2107-14. 2004
    ..The data suggest that restoration of DEP-1/HPTPeta expression could be a useful tool for the gene therapy of human pancreatic cancers...
  94. pmc An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues
    Chang Gong Liu
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 101:9740-4. 2004
    ..The microchip oligolibrary can be expanded to include an increasing number of miRNAs discovered in various species and is useful for the analysis of normal and disease states...
  95. ncbi request reprint The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis
    Tamotsu Kuroki
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Clin Cancer Res 10:2459-65. 2004
    ..We showed previously that WWOX is frequently altered in human lung and esophageal cancers. The purpose of this study was to delineate more precisely the role of WWOX in pancreatic carcinogenesis...
  96. pmc Functional association between Wwox tumor suppressor protein and p73, a p53 homolog
    Rami I Aqeilan
    Kimmel Cancer Institute, Thomas Jefferson University, 233 South 10th Street, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 101:4401-6. 2004
    ..In addition, we show that cytoplasmic p73 contributes to the proapoptotic activity of Wwox. Our findings reveal a functional cross-talk between p73 and Wwox tumor suppressor protein...
  97. ncbi request reprint Allelic loss on chromosome 3p21.3 and promoter hypermethylation of semaphorin 3B in non-small cell lung cancer
    Tamotsu Kuroki
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Res 63:3352-5. 2003
    ..These results indicate that SEMA3B gene alterations may play a important role in the malignant transformation of NSCLC via a two-hit mechanism, including epigenetic changes and allelic loss, for tumor suppressor gene inactivation...
  98. pmc MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias
    George Adrian Calin
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Proc Natl Acad Sci U S A 101:11755-60. 2004
    ..These data suggest that miRNA expression patterns have relevance to the biological and clinical behavior of this leukemia...
  99. ncbi request reprint FHIT as tumor suppressor: mechanisms and therapeutic opportunities
    Yuri Pekarsky
    Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Cancer Biol Ther 1:232-6. 2002
    ..This review focuses on the most recent progress in understanding of Fhit function as a tumor suppressor and opportunities for gene cancer therapy with Fhit...
  100. ncbi request reprint WWOX in biological control and tumorigenesis
    Rami I Aqeilan
    Department of Molecular Virology, Immunology and Medical Genetics, Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    J Cell Physiol 212:307-10. 2007
    ..This review focuses on the most recent progress in understanding WWOX function as a tumor suppressor...

Research Grants27

  1. FHIT Gene Therapy in Cancer Prevention and Treatment
    Carlo Croce; Fiscal Year: 2009
    ..abstract_text> ..
  2. MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma
    Carlo M Croce; Fiscal Year: 2010
    ..We have defined deregulation of specific microRNAs in HCC. We intend to exploit this knowledge to develop targeted therapies of HCC based on the correction of microRNA dysregulation. ..
  3. ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri
    Carlo Croce; Fiscal Year: 2006
    ....
  4. ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri
    Carlo Croce; Fiscal Year: 2007
    ....
  5. Role of miR155 in Leukemogenesis
    Carlo Croce; Fiscal Year: 2009
    ..This will provide the basis for the development of antimiR155 therapies in human cancer. ..
  6. ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri
    Carlo Croce; Fiscal Year: 2009
    ....
  7. ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri
    Carlo M Croce; Fiscal Year: 2010
    ..abstract_text> ..
  8. FHIT Gene Therapy in Cancer Prevention and Treatment
    Carlo Croce; Fiscal Year: 2007
    ....
  9. MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma
    Carlo M Croce; Fiscal Year: 2011
    ..We have defined deregulation of specific microRNAs in HCC. We intend to exploit this knowledge to develop targeted therapies of HCC based on the correction of microRNA dysregulation. ..
  10. ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS
    Carlo Croce; Fiscal Year: 2001
    ..Acute lymphoblastic and acute myelogenous leukemias will be investigated for the expression, rearrangements and mutations of ALL-1 target genes. ..
  11. ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS
    Carlo Croce; Fiscal Year: 2000
    ..Acute lymphoblastic and acute myelogenous leukemias will be investigated for the expression, rearrangements and mutations of ALL-1 target genes. ..
  12. 8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA
    Carlo Croce; Fiscal Year: 2002
    ..We will also determine whether Fez1 loss of function makes cancer cells more resistant to chemotherapeutic drugs. Finally, we will determine whether FHIT and Fez1 are collaborating tumor suppressor genes ..
  13. ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS
    Carlo Croce; Fiscal Year: 2002
    ..Acute lymphoblastic and acute myelogenous leukemias will be investigated for the expression, rearrangements and mutations of ALL-1 target genes. ..
  14. 8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA
    Carlo Croce; Fiscal Year: 2003
    ..We will also determine whether Fez1 loss of function makes cancer cells more resistant to chemotherapeutic drugs. Finally, we will determine whether FHIT and Fez1 are collaborating tumor suppressor genes ..
  15. 8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA
    Carlo Croce; Fiscal Year: 2004
    ..We will also determine whether Fez1 loss of function makes cancer cells more resistant to chemotherapeutic drugs. Finally, we will determine whether FHIT and Fez1 are collaborating tumor suppressor genes ..
  16. FHIT Gene Therapy in Cancer Prevention and Treatment
    Carlo M Croce; Fiscal Year: 2011
    ..abstract_text> ..
  17. ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS
    Carlo Croce; Fiscal Year: 1999
    ..Acute lymphoblastic and acute myelogenous leukemias will be investigated for the expression, rearrangements and mutations of ALL-1 target genes. ..
  18. Role of miR155 in Leukemogenesis
    Carlo M Croce; Fiscal Year: 2010
    ..This will provide the basis for the development of antimiR155 therapies in human cancer. ..
  19. FHIT Gene Therapy in Cancer Prevention and Treatment
    Carlo M Croce; Fiscal Year: 2010
    ..abstract_text> ..
  20. 8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA
    Carlo Croce; Fiscal Year: 2000
    ..We will also determine whether Fez1 loss of function makes cancer cells more resistant to chemotherapeutic drugs. Finally, we will determine whether FHIT and Fez1 are collaborating tumor suppressor genes ..
  21. MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma
    Carlo Croce; Fiscal Year: 2009
    ..We have defined deregulation of specific microRNAs in HCC. We intend to exploit this knowledge to develop targeted therapies of HCC based on the correction of microRNA dysregulation. ..
  22. 8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA
    Carlo Croce; Fiscal Year: 2001
    ..We will also determine whether Fez1 loss of function makes cancer cells more resistant to chemotherapeutic drugs. Finally, we will determine whether FHIT and Fez1 are collaborating tumor suppressor genes ..
  23. 8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA
    Carlo Croce; Fiscal Year: 2004
    ..We will also determine whether Fez1 loss of function makes cancer cells more resistant to chemotherapeutic drugs. Finally, we will determine whether FHIT and Fez1 are collaborating tumor suppressor genes ..